DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Gordon LI, Witzig T, Molina A. et al.
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Clin Lymphoma 2004; 5: 98-101
We do not assume any responsibility for the contents of the web pages of other providers.